Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11682047 | 0.88 | MAPT (0.67) | TP53GAAALDH1A1LMNATHRB | |
| SCHEMBL11727445 | 0.82 | PKM (0.73) | PKMTP53GAAALDH1A1LMNA | |
| SCHEMBL28942578 | 0.81 | ALDH1A1 (0.61) | PKMTP53GAAALDH1A1LMNA | |
| SCHEMBL21629314 | 0.78 | TP53 (0.73) | PKMTP53GAAALDH1A1LMNA | |
| SCHEMBL16624687 | 0.78 | ALDH1A1 (0.55) | PKMTP53GAAALDH1A1LMNA | |
| SCHEMBL11638581 | 0.77 | PKM (0.62) | PKMTP53GAAALDH1A1LMNA | |
| SCHEMBL7000095 | 0.77 | KDM4E (0.67) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL2921293 | 0.76 | PKM (0.64) | PKMTP53GAAALDH1A1LMNA | |
| SCHEMBL14916767 | 0.76 | SMN1; SMN2 (0.68) | TP53GAAALDH1A1LMNATHRB | |
| Hydrochloric Acid SCHEMBL11854537 | 0.74 | MAPT (0.59) | PKMTP53GAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510025-B1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-110248934-B | Heteroaryl PAD4 inhibitors | 帕德罗科治疗公司 | 2022-05-24 | — | — | CN | disclosed |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-09-30 | — | — | US | disclosed |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3510025-A1 | HETEROARYL INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018049296-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | PKM 1823/4885TP53 1404/4885GAA 904/4885 |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | PKM 1823/4885TP53 1404/4885GAA 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.